Anti-Hypertensive Drugs Market
The Business Research Company offers “Anti-Hypertensive Drugs Global Market Report 2020-30: Covid 19 Impact And Recovery” in its research report store. It is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies. The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by region and by country. It also compares the market’s historic and forecast growth, and highlights important trend s and strategies that players in the market can adopt.
The global anti-hypertensive drugs market is expected to decline from $26.1 billion in 2019 to $23.5 billion in 2020 at a compound annual growth rate (CAGR) of -9.7%. The decline is mainly because of the lockdown measures due to the COVID-19 outbreak. The decrease in the number of cardiac surgeries due to re-scheduling of surgeries, cancellations and no-show by patients, decrease in consultations due to restrictions by government and health authorities to provide only emergency services, and less heart disease admissions contribute to this decline. However, the decline is not significant as research showed that the covid patients developed cardiovascular complications, and therefore health authorities advised covid and non-covid cardiac patients to continue the use of CVD drugs. The market is then expected to recover and grow at a CAGR of 2.8% from 2021 and reach $27.7 billion in 2023.
Place a DIRECT PURCHASE ORDER of The Entire 140+ Pages Report @ https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2410
The anti-hypertensive drugs market consists of sales of anti-hypertensive drugs and related services. These drugs are re used to prevent heart failure, kidney failure and acute stroke induced by hypertension.
Low awareness of the antihypertensive drugs amongst the population is one of the major restraints in the Anti-Hypertensive Drugs market. Firstly, most of the people in developing nations neglect their health-checkups and are not aware about the existing hypertension condition in them until they detect extreme symptoms Secondly, persons diagnosed with hypertension are not adherent to their medication schedule and stop taking medication after 1-2 weeks until symptoms return, thereby posing a huge challenge to the anti-hypertensive drugs market.
Anti-Hypertensive Drugs Market Segmentation:
2.Angiotensin Receptor Blockers (ARBs)
3.Angiotensin Converting Enzyme (ACE) Inhibitors
6.Calcium Channel Blockers
By Disease Source
By End Users
Browse Complete Report @ https://www.thebusinessresearchcompany.com/report/anti-hypertensive-drugs-global-market-report
Few Points From Table Of Content
1. Executive Summary
2. Anti-Hypertensive Drugs Market Characteristics
3. Anti-Hypertensive Drugs Market Size And Growth
4. Anti-Hypertensive Drugs Market Segmentation
5. Anti-Hypertensive Drugs Market Regional And Country Analysis
26. Key Mergers And Acquisitions In The Anti-Hypertensive Drugs Market
27. Anti-Hypertensive Drugs Market Trends And Strategies
28. Product Pipeline Analysis
29. Anti-Hypertensive Drugs Market Future Outlook and Potential Analysis
The report covers the trends and market dynamics of the anti-hypertensive drugs market in major countries – Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The report also includes consumer surveys and various future opportunities for the market.
Request for a Sample Copy of This Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=2410&type=smp
Some of the key players involved in the anti-hypertensive drugs market are Merck & Co. Inc., Astra Zeneca Plc, Daiichi Sankyo Company Limited, Johnson & Johnson Ltd., Pfizer, Inc
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Follow us on Blog: http://blog.tbrc.info/
The Business Research Company has published over 1000 industry reports, covering over 2500 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets after WHO declared COVID-19 as a pandemic.
This release was published on openPR.